- Alkermes plc Reports First Quarter 2024 Financial Results
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
- Alkermes to Report First Quarter Financial Results on May 1, 2024
- Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
- Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
- Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
- Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
- Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
More ▼
Key statistics
As of last trade Alkermes Plc (ALKS:NSQ) traded at 23.85, 8.34% above its 52-week low of 22.01, set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.85 |
---|---|
High | 24.17 |
Low | 23.26 |
Bid | 23.77 |
Offer | 23.92 |
Previous close | 24.54 |
Average volume | 1.68m |
---|---|
Shares outstanding | 169.18m |
Free float | 167.07m |
P/E (TTM) | 8.12 |
Market cap | 4.15bn USD |
EPS (TTM) | 3.02 USD |
Data delayed at least 15 minutes, as of May 01 2024 14:37 BST.
More ▼